Pucotenlimab: all 41 studies that test it

Page 1 of 1. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.

• Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerRecruitingNCT07884188Phase 2
• Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile CancerNot yet recruitingNCT07767266Phase 2
• Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07766889Phase 2
• Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant MelanomaRecruitingNCT07750067Phase 2
• Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-PositiveRecruitingNCT07712029Phase 2
• Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingNCT07692334Phase 2
• Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell CarcinomaRecruitingNCT07665190Phase 2
• Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase IINot yet recruitingNCT07649980Phase 2
• Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung CancerNot yet recruitingNCT07627321Phase 2
• Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II StudyNot yet recruitingNCT07589049Phase 2
• Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)Not yet recruitingNCT07545083Phase 2
• EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile CancerRecruitingNCT07518979Phase 2
• Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal CancerRecruitingNCT07448142Phase 2
• Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingNCT07394244Phase 2
• MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical TrialNot yet recruitingNCT07381699Phase 2
• FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07353827Phase 2
• LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm StudyRecruitingNCT07312422Phase 1/2
• Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenRecruitingNCT07188311Not applicable
• MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell CarcinomaRecruitingNCT07054307Phase 1
• A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaRecruitingNCT06976190Phase 3
• Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and NeckRecruitingNCT06959108Phase 2
• The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCCNot yet recruitingNCT06895369Phase 2
• Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal CancerNot yet recruitingNCT06872606Phase 2
• Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)RecruitingNCT06770270Phase 2
• A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06530914Phase 2
• Effectiveness of Pucotenlimab Combined With Standard Chemotherapy RegimenRecruitingNCT06456892Phase 1/2
• Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192797Phase 2
• Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192784Phase 2
• A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsRecruitingNCT05688605Phase 1/2
• OH2 Injection in Combination With HX008 for Melanoma.RecruitingNCT04616443Phase 1/2
• A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal CancerActive, not recruitingNCT05652894Phase 3
• A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.Status unknownNCT05338957Phase 1/2
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckCompletedNCT04868162Phase 2
• A Phase Ib Study of HX008 in Patients With Advanced Solid TumorsStatus unknownNCT04825392Phase 1
• A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced MelanomaStatus unknownNCT04756934Phase 1
• A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast CancerStatus unknownNCT04750382Phase 1/2
• HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung CancerStatus unknownNCT04750083Phase 2/3
• A Study of HX008 for the Treatment of Patients With Malignant MelanomaStatus unknownNCT04749485Phase 2
• Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerStatus unknownNCT04738630Phase 2
• Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)Status unknownNCT04574817Phase 2
• HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Phase 3

← Pucotenlimab overview